blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2588469

EP2588469 - HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  22.05.2015
Database last updated on 07.10.2024
Most recent event   Tooltip22.05.2015Application deemed to be withdrawnpublished on 24.06.2015  [2015/26]
Applicant(s)For all designated states
Amgen Inc.
One Amgen Center Drive
Thousand Oaks, California 91320-1799 / US
[2013/19]
Inventor(s)01 / DUQUETTE, Jason A.
460 Bayview Avenue
Millbrae, California 94030 / US
02 / LUCAS, Brian
133 10th Avenue
San Francisco, California 94118 / US
 [2013/19]
Representative(s)Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastrasse 30
81925 München / DE
[N/P]
Former [2013/19]HOFFMANN EITLE
Patent- und Rechtsanwälte
Arabellastrasse 4
81925 München / DE
Application number, filing date11730846.030.06.2011
WO2011US42519
Priority number, dateUS20100361014P02.07.2010         Original published format: US 361014 P
[2013/19]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2012003271
Date:05.01.2012
Language:EN
[2012/01]
Type: A1 Application with search report 
No.:EP2588469
Date:08.05.2013
Language:EN
The application published by WIPO in one of the EPO official languages on 05.01.2012 takes the place of the publication of the European patent application.
[2013/19]
Search report(s)International search report - published on:EP05.01.2012
ClassificationIPC:C07D401/12, C07D487/04, A61P29/00, A61P35/00, A61K31/4709
[2013/19]
CPC:
C07D401/12 (EP,US); C07D473/34 (US); A61P1/04 (EP);
A61P13/10 (EP); A61P17/00 (EP); A61P17/06 (EP);
A61P19/02 (EP); A61P21/04 (EP); A61P25/00 (EP);
A61P27/02 (EP); A61P29/00 (EP); A61P35/00 (EP);
A61P37/06 (EP); A61P37/08 (EP); A61P7/04 (EP);
A61P7/06 (EP); C07D401/14 (US); C07D487/04 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/19]
Extension statesBA16.01.2013
ME16.01.2013
TitleGerman:HETEROZYKLISCHE VERBINDUNGEN UND IHRE VERWENDUNG ALS HEMMER DER PI3K-AKTIVITÄT[2013/19]
English:HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY[2013/19]
French:COMPOSÉS HÉTÉROCYCLIQUES ET LEUR UTILISATION COMME INHIBITEURS DE L'ACTIVITÉ PI3K[2013/19]
Entry into regional phase16.01.2013National basic fee paid 
16.01.2013Designation fee(s) paid 
16.01.2013Examination fee paid 
Examination procedure16.01.2013Amendment by applicant (claims and/or description)
16.01.2013Examination requested  [2013/19]
05.09.2014Despatch of a communication from the examining division (Time limit: M04)
16.01.2015Application deemed to be withdrawn, date of legal effect  [2015/26]
09.02.2015Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2015/26]
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  05.09.2014
Fees paidRenewal fee
10.06.2013Renewal fee patent year 03
12.06.2014Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[XI]WO2008118468  (AMGEN INC [US]) [X] 1-4 * page 9, line 25 - page 10, line 10 * * example 30 * * claims 1,9 * [I] 1-4;
 [A]WO2009081105  (UCB PHARMA SA [BE], et al) [A] 1-4 * page 2, line 27 - line 30 ** claim 1 *;
 [I]WO2010036380  (INTELLIKINE INC [US], et al) [I] 1-4 * claims 1,23 *;
 [XPI]WO2010092340  (UCB PHARMA SA [BE], et al) [XP] 1-4 * page 2, paragraph second last * * examples 1-3,5-7,11,13,16,35-37,69-71,92,95,97 * * claim 1 * [I] 1-4;
 [XPI]WO2011058113  (UCB PHARMA SA [BE], et al) [XP] 1-4 * page 22, line 18 - line 19 * * example 6 * * claims 1,13-14 * [I] 1-4;
 [AP]WO2011058111  (UCB PHARMA SA [BE], et al) [AP] 1-4 * page 22, line 19 - line 20 * * claims 1,15-16 *;
 [XPI]WO2011075628  (AMGEN INC [US], et al) [XP] 1-4 * page 10, line 1 - line 14 * * claims 1,3 * [I] 1-4
by applicantEP0039051
 WO9625488
 WO9746688
 US5822910
 US5858753
 US5985589
 WO2008118468
    - RAMEH ET AL., J. BIOL CHEM, (1999), vol. 274, pages 8347 - 8350
    - PANAYOTOU, TRENDS CELL BIOL, (1992), vol. 2, pages 358 - 60
    - CANTLEY, SCIENCE, (2002), vol. 296, pages 1655 - 1657
    - VANHAESEBROECK ET AL., ANNU.REV.BIOCHEM, (2001), vol. 70, pages 535 - 602
    - PARKER ET AL., CURRENT BIOLOGY, (1995), vol. 5, pages 577 - 99
    - YAO ET AL., SCIENCE, (1995), vol. 267, pages 2003 - 05
    - STERNMARK ET AL., J CELL SCI, (1999), vol. 112, pages 4175 - 83
    - LEMMON ET AL., TRENDS CELL BIOL, (1997), vol. 7, pages 237 - 42
    - SCHAEFFER, SCHWARTZBERG, CURR.OPIN.IMMUNO, (2000), vol. 12, pages 282 - 288
    - DEANE, FRUMAN, ANNU.REV.IMMUNOL., (2004), vol. 22, pages 563 - 598
    - BURGERING ET AL., NATURE, (1995), vol. 376, pages 599 - 602
    - OTSU ET AL., CELL, (1991), vol. 65, pages 91 - 104
    - HILES ET AL., CELL, (1992), vol. 70, pages 419 - 29
    - HU ET AL., MOL CELL BIOL, (1993), vol. 13, pages 7677 - 88
    - CHANTRY ET AL., J BIOL CHEM, (1997), vol. 272, pages 19236 - 41
    - AL-ALWAN, JI, (2007), vol. 178, pages 2328 - 2335
    - OKKENHAUG ET AL., JI, (2006), vol. 177, pages 5122 - 5128
    - LEE ET AL., PNAS, (2006), vol. 103, pages 1289 - 1294
    - VOGT ET AL., VIROLOGY, (2006), vol. 344, pages 131 - 138
    - SAWYER, CANCER RES., (2003), vol. 63, pages 1667 - 1675
    - VANHAESEBROECK ET AL., PROC NAT. ACAD SCI USA, (1997), vol. 94, pages 4330 - 5
    - RAMEH ET AL., CELL, (1995), vol. 83, pages 821 - 30
    - VOLINIA ET AL., ONCOGENE, (1992), vol. 7, pages 789 - 93
    - STOYANOV ET AL., SCIENCE, (1995), vol. 269, pages 690 - 93
    - KRUGMANN ET AL., J BIOL CHEM, (1999), vol. 274, pages 17152 - 8
    - VOIGT ET AL., JBC, (2006), vol. 281, pages 9977 - 9986
    - SUIRE ET AL., CURR.BIOL., (2005), vol. 15, pages 566 - 570
    - KLIPPEL ET AL., MOL CELL BIOL, (1994), vol. 14, pages 2675 - 85
    - HUNTER, CELL, (1995), vol. 83, pages 1 - 4
    - PAGES ET AL., NATURE, (1994), vol. 369, pages 327 - 29
    - RUDD, IMMUNITY, (1996), vol. 4, pages 527 - 34
    - FRASER ET AL., SCIENCE, (1991), vol. 251, pages 313 - 16
    - FRUMAN ET AL., ANN REV BIOCHEM, (1998), vol. 67, pages 481 - 507
    - THELEN ET AL., PROC NATL ACAD SCI USA, (1994), vol. 91, pages 4960 - 64
    - BI ET AL., MAMM.GENOME, (2002), vol. 13, pages 169 - 172
    - BI ET AL., J.BIOL.CHEM., (1999), vol. 274, pages 10963 - 10968
    - FOUKAS ET AL., NATURE, (2006), vol. 441, pages 366 - 370
    - LI ET AL., SCIENCE, (2000), vol. 287, pages 1046 - 1049
    - SASAKI ET AL., SCIENCE, (2000), vol. 287, pages 1040 - 1046
    - PATRUCCO ET AL., CELL, (2004), vol. 118, pages 375 - 387
    - CLAYTON ET AL., J.EXP.MED., (2002), vol. 196, pages 753 - 763
    - OKKENHAUG ET AL., SCIENCE, (2002), vol. 297, pages 1031 - 1034
    - OKKENHAUG ET AL., J.IMMUNOL., (2006), vol. 177, pages 5122 - 5128
    - JOU ET AL., INT.J.IMMUNOGENET, (2006), vol. 33, pages 361 - 369
    - ITO ET AL., J. PHARM. EXP. THERAPEUT., (2007), vol. 321, pages 1 - 8
    - HENNESSY ET AL., NATURE REVIEWS, (2005), vol. 4, pages 988 - 1004
    - ITO ET AL., J.PHARM.EXP.THERAPEUT., (2007), vol. 321, pages 1 - 8
    - JACKSON ET AL., NATURE MED., (2005), vol. 11, pages 507 - 514
    - RUECKLE ET AL., NATURE REVIEWS, (2006), vol. 5, pages 903 - 918
    - CAMPS ET AL., NATURE MEDICINE, (2005), vol. 11, pages 936 - 943
    - BARBER ET AL., NATURE MEDICINE, vol. 11, pages 933 - 935
    - KNIGHT ET AL., CELL, (2006), vol. 125, pages 733 - 747
    - CONDLIFFE ET AL., BLOOD, (2005), vol. 106, pages 1432 - 1440
    - ALI ET AL., NATURE, (2002), vol. 431, pages 1007 - 1011
    - LEE ET AL., FASEB, (2006), vol. 20, pages 455 - 465
    - NASHED ET AL., EUR.J.IMMUNOL., (2007), vol. 37, pages 416 - 424
    - BERGE ET AL., J. PHARM. SCI, (1977), vol. 66, page 1
    - SVENSSON, TUNEK, DRUG METABOLISM REVIEWS, (1988), vol. 165
    - BUNGAARD, J. MED. CHEM., (1989), page 2503
    - SVENSSON, TUNEK, Drug Metabolism Reviews, (1988), vol. 165
 US20140613610
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.